维普中文期刊产品整合服务

MicroRNA-126 and epidermal growth factor-like domain 7 predict recurrence in patients with colon cancer treated with neoadjuvant chemotherapy

查看全文 作　　者：Torben Frøstrup [1]Hansen;Anting Liu [2,3]Carlsen;Julia Tanas [2]Tanassi;Ole [4]Larsen;Flemming Brandt [1,5]Sørensen;Lars Henrik [1]Jensen;Anders [1]Jakobsen 高影响力作者 机构地区：[1]Danish Colorectal Cancer Center South,Vejle Hospital,Institute of Regional Health Research,University of Southern Denmark,Vejle 7100,Denmark;[2]Department of Autoimmunology and Biomarkers,Statens Serum Institut,Copenhagen 2300,Denmark;[3]Department of Congenital Disorders,Statens Serum Institut,Copenhagen 2300,Denmark;[4]Department of Oncology,Herlev Hospital,Herlev 2730,Denmark;[5]University Institute of Pathology,Aarhus University Hospital,and department of Clinical Medicine,University of Aarhus,Aarhus 8200,Denmark高影响力机构 出　　处：《Cancer Drug Resistance》索引2019年第2卷第3期,共12页高影响力期刊 基　　金：This work was supported by the Cancer Foundation(no reference),the Danish Council for Independent Research(No.10-093589);Direktør Jacob Madsen&Hustru Olga Madsen’s Foundation(No.5297);the Regional Strategic Council for Research in the Region of Southern Denmark(No.14/32395). 摘　　要：Aim:Neoadjuvant chemotherapy may represent a shift in the treatment of locally advanced colon cancer.The angiogenic couple has-microRNA-126(miRNA-126)and epidermal growth factor-like domain 7(EGFL7)are transcribed from the same gene and regulates all aspects of angiogenesis and may influence the ability of tumor cells to disseminate.The aim was to analyze the relationship between miRNA-126 and EGFL7 and disease recurrence in patients with locally advanced colon cancer treated with neoadjuvant chemotherapy.Methods:This study included 71 patients from a phase II study all planned for three cycles of capecitabine and oxaliplatin before surgery.Blood was sampled at baseline and right before and after the operation.Circulating miRNA-126 was analysed by RT-qPCR and a quantitative immunoassay was used for the analyses of EGFL7.Results:The rates of 5-year disease-free survival(DFS)and overall survival(OS)were 80%and 85%,respectively.The level of circulating miRNA-126 before the operation predicts recurrence,P=0.035.In patients with values below and above the median the recurrence rate was 31%and 4%,respectively.Similar results applied to EGFL7.A combined estimate identified a subgroup of patients(25 of 71)with no recurrence and a 5-year DFS and OS rate of 100%,respectively.Conclusion:MicroRNA-126 and EGFL7 are predictors for disease recurrence in patients with locally advanced colon cancer treated with neoadjuvant chemotherapy and may assist in selection of adjuvant chemotherapy. 关 键 词：CHEMOTHERAPY colon cancer epidermal growth factor-like domain 7 microRNA-126
相关文献

参考文献(34)

引证文献(1)

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费